FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Stem Cells Transl Med / Engineered Mesenchymal Cells Improve Passive Immune Protecti...
Stem cells translational medicine2016; 5(8); 1026-1035; doi: 10.5966/sctm.2015-0341

Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.

Abstract: : Mesenchymal stromal cells (MSCs) are being exploited as gene delivery vectors for various disease and injury therapies. We provide proof-of-concept that engineered MSCs can provide a useful, effective platform for protection against infectious disease. Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne pathogen affecting humans and equines and can be used in bio-warfare. No licensed vaccine or antiviral agent currently exists to combat VEEV infection in humans. Direct antibody administration (passive immunity) is an effective, but short-lived, method of providing immediate protection against a pathogen. We compared the protective efficacy of human umbilical cord perivascular cells (HUCPVCs; a rich source of MSCs), engineered with a transgene encoding a humanized VEEV-neutralizing antibody (anti-VEEV), to the purified antibody. In athymic mice, the anti-VEEV antibody had a half-life of 3.7 days, limiting protection to 2 or 3 days after administration. In contrast, engineered HUCPVCs generated protective anti-VEEV serum titers for 21-38 days after a single intramuscular injection. At 109 days after transplantation, 10% of the mice still had circulating anti-VEEV antibody. The mice were protected against exposure to a lethal dose of VEEV by an intramuscular pretreatment injection with engineered HUCPVCs 24 hours or 10 days before exposure, demonstrating both rapid and prolonged immune protection. The present study is the first to describe engineered MSCs as gene delivery vehicles for passive immunity and supports their utility as antibody delivery vehicles for improved, single-dose prophylaxis against endemic and intentionally disseminated pathogens. Direct injection of monoclonal antibodies (mAbs) is an important strategy to immediately protect the recipient from a pathogen. This strategy is critical during natural outbreaks or after the intentional release of bio-weapons. Vaccines require weeks to become effective, which is not practical for first responders immediately deployed to an infected region. However, mAb recipients often require booster shots to maintain protection, which is expensive and impractical once the first responders have been deployed. The present study has shown, for the first time, that mesenchymal stromal cells are effective gene delivery vehicles that can significantly improve mAb-mediated immune protection in a single, intramuscular dose of engineered cells. Such a cell-based delivery system can provide extended life-saving protection in the event of exposure to biological threats using a more practical, single-dose regimen.
©AlphaMed Press.
Get Full Text
Publication Date: 2016-06-22 PubMed ID: 27334491PubMed Central: PMC4954456DOI: 10.5966/sctm.2015-0341Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research study demonstrates how genetically engineered cells from the human umbilical cord can provide long-lasting protection against lethal exposure to Venezuelan equine encephalitis virus. The results offer potential implications for developing protection methods against infectious diseases, especially in instances of bio-warfare.

Background and Aim of Study

  • Venezuelan equine encephalitis virus (VEEV) is a potentially lethal mosquito-borne pathogen that can affect both humans and horses.
  • As yet, no approved vaccine or antiviral agent is available to combat VEEV infection in humans.
  • This research aimed to investigate the effectiveness of Mesenchymal stromal cells (MSCs) as gene delivery vectors for disease protection, specific to VEEV.

Approach and Findings

  • The researchers used human umbilical cord perivascular cells (HUCPVCs), a rich source of MSCs. These cells were engineered with a gene encoding a humanized antibody capable of neutralizing VEEV.
  • Compared to the purified antibody, these engineered HUCPVCs generated protective anti-VEEV serum levels for 21-38 days after a single intramuscular injection, with 10% of mice having circulating anti-VEEV antibodies up to 109 days after transplantation.
  • This contrasts to the direct delivery of the antibody, which had a half-life of 3.7 days, meaning its protective effect only lasted 2 to 3 days post-administration.
  • The mice were effectively protected against lethal doses of VEEV when pre-treated with an intramuscular injection of the engineered HUCPVCs 24 hours or 10 days prior to exposure.

Significance and Implications

  • This research represents the first study demonstrating the effectiveness of engineered MSCs as gene delivery vehicles for passive immunity.
  • As such, these cells hold promise as antibody delivery vehicles for improving prophylaxis against endangered and deliberately disseminated pathogens, offering extended protection or even potentially life-saving effects.
  • This strategy could be particularly important for providing immediate protection during natural outbreaks or bio-weapon release events, offsetting the impracticalities and costs associated with regular injections of monoclonal antibodies (mAbs).
  • Applications could extend to first responders and those deployed to infected regions, who require immediate, long-lasting protection against infectious diseases.

Cite This Article

APA
Braid LR, Hu WG, Davies JE, Nagata LP. (2016). Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure. Stem Cells Transl Med, 5(8), 1026-1035. https://doi.org/10.5966/sctm.2015-0341

Publication

Stem cells translational medicine
ISSN: 2157-6564
NlmUniqueID: 101578022
Country: England
Language: English
Volume: 5
Issue: 8
Pages: 1026-1035

Researcher Affiliations

Braid, Lorena R
  • Bio-Threat Defence Section, Defence Research and Development Canada, Suffield Research Centre, Ralston, Alberta, Canada Aurora BioSolutions Inc., Medicine Hat, Alberta, Canada.
Hu, Wei-Gang
  • Bio-Threat Defence Section, Defence Research and Development Canada, Suffield Research Centre, Ralston, Alberta, Canada wei-gang.hu@drdc-rddc.gc.ca.
Davies, John E
  • Institute of Biomaterials and Bioengineering, University of Toronto, Toronto, Ontario, Canada Tissue Regeneration Therapeutics, Inc., Toronto, Ontario, Canada.
Nagata, Les P
  • Bio-Threat Defence Section, Defence Research and Development Canada, Suffield Research Centre, Ralston, Alberta, Canada.

MeSH Terms

  • Animals
  • Antibodies, Monoclonal, Humanized / biosynthesis
  • Antibodies, Monoclonal, Humanized / genetics
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Neutralizing / biosynthesis
  • Antibodies, Neutralizing / genetics
  • Antibodies, Neutralizing / immunology
  • Cells, Cultured
  • Encephalitis Virus, Venezuelan Equine / immunology
  • Encephalitis Virus, Venezuelan Equine / pathogenicity
  • Encephalomyelitis, Venezuelan Equine / immunology
  • Encephalomyelitis, Venezuelan Equine / prevention & control
  • Encephalomyelitis, Venezuelan Equine / virology
  • Female
  • Genetic Therapy / methods
  • Genotype
  • Half-Life
  • Host-Pathogen Interactions
  • Humans
  • Injections, Intramuscular
  • Mesenchymal Stem Cells / immunology
  • Mesenchymal Stem Cells / metabolism
  • Mesenchymal Stem Cells / virology
  • Mice, Inbred BALB C
  • Mice, Nude
  • Phenotype
  • Protein Stability
  • Transfection
  • Umbilical Cord / cytology
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / genetics
  • Viral Vaccines / immunology
  • Viral Vaccines / pharmacokinetics

References

This article includes 59 references
  1. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing.. Stem Cells 2007 Nov;25(11):2739-49.
    pubmed: 17656645doi: 10.1634/stemcells.2007-0197google scholar: lookup
  2. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells.. Blood 2007 Nov 15;110(10):3499-506.
    pubmed: 17664353doi: 10.1182/blood-2007-02-069716google scholar: lookup
  3. Atoui R, Chiu RC. Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns.. Stem Cells Transl Med 2012 Mar;1(3):200-5.
    pmc: PMC3659851pubmed: 23197779doi: 10.5966/sctm.2011-0012google scholar: lookup
  4. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, McIntosh KR. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression.. J Biomed Sci 2005;12(1):47-57.
    pubmed: 15864738doi: 10.1007/s11373-004-8183-7google scholar: lookup
  5. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses.. Blood 2005 Feb 15;105(4):1815-22.
    pubmed: 15494428doi: 10.1182/blood-2004-04-1559google scholar: lookup
  6. Hodgkinson CP, Gomez JA, Mirotsou M, Dzau VJ. Genetic engineering of mesenchymal stem cells and its application in human disease therapy.. Hum Gene Ther 2010 Nov;21(11):1513-26.
    pmc: PMC2978545pubmed: 20825283doi: 10.1089/hum.2010.165google scholar: lookup
  7. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells.. Gene Ther 2008 May;15(10):711-5.
    pubmed: 18356815doi: 10.1038/gt.2008.35google scholar: lookup
  8. Yan C, Li S, Li Z, Peng H, Yuan X, Jiang L, Zhang Y, Fan D, Hu X, Yang M, Xiong D. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.. Mol Pharm 2013 Jan 7;10(1):142-51.
    pubmed: 23121392doi: 10.1021/mp300261egoogle scholar: lookup
  9. Frank RT, Najbauer J, Aboody KS. Concise review: stem cells as an emerging platform for antibody therapy of cancer.. Stem Cells 2010 Nov;28(11):2084-7.
    pmc: PMC3003900pubmed: 21089119doi: 10.1002/stem.513google scholar: lookup
  10. Compte M, Cuesta AM, Sánchez-Martín D, Alonso-Camino V, Vicario JL, Sanz L, Alvarez-Vallina L. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds.. Stem Cells 2009 Mar;27(3):753-60.
    pmc: PMC2729675pubmed: 19096041doi: 10.1634/stemcells.2008-0831google scholar: lookup
  11. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts.. Nat Med 2003 Sep;9(9):1195-201.
    pubmed: 12910262doi: 10.1038/nm912google scholar: lookup
  12. Balyasnikova IV, Ferguson SD, Sengupta S, Han Y, Lesniak MS. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma.. PLoS One 2010 Mar 18;5(3):e9750.
    pmc: PMC2841188pubmed: 20305783doi: 10.1371/journal.pone.0009750google scholar: lookup
  13. Balyasnikova IV, Franco-Gou R, Mathis JM, Lesniak MS. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface.. J Tissue Eng Regen Med 2010 Jun;4(4):247-58.
    pmc: PMC2880221pubmed: 19937911doi: 10.1002/term.228google scholar: lookup
  14. Young JS, Kim JW, Ahmed AU, Lesniak MS. Therapeutic cell carriers: a potential road to cure glioma.. Expert Rev Neurother 2014 Jun;14(6):651-60.
    pubmed: 24852229doi: 10.1586/14737175.2014.917964google scholar: lookup
  15. Wyse RD, Dunbar GL, Rossignol J. Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.. Int J Mol Sci 2014 Jan 23;15(2):1719-45.
    pmc: PMC3958818pubmed: 24463293doi: 10.3390/ijms15021719google scholar: lookup
  16. Cucchiarini M, Venkatesan JK, Ekici M, Schmitt G, Madry H. Human mesenchymal stem cells overexpressing therapeutic genes: from basic science to clinical applications for articular cartilage repair.. Biomed Mater Eng 2012;22(4):197-208.
    pubmed: 22785363doi: 10.3233/bme-2012-0709google scholar: lookup
  17. Liu LN, Wang G, Hendricks K, Lee K, Bohnlein E, Junker U, Mosca JD. Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models.. Stem Cells Transl Med 2013 May;2(5):362-75.
    pmc: PMC3667563pubmed: 23592838doi: 10.5966/sctm.2012-0135google scholar: lookup
  18. Wang G, Lui LN, Keunmyoung L. Comparison of drug and cell-based delivery—Engineering adult mesenchymal cells to deliver human erythropoietin. Gene Ther Mol Biol 2009;13:321–330.
  19. Hu WG, Nagata LP. Antibody gene-based prophylaxis and therapy for biodefence.. Hum Vaccin 2008 Jan-Feb;4(1):74-8.
    pubmed: 18376146doi: 10.4161/hv.4.1.4778google scholar: lookup
  20. Nagata LP, Wong JP, Hu WG. Vaccines and therapeutics for the encephalitic alphaviruses. Future Virol 2013;8:661–674.
  21. Ho DT, Wykoff-Clary S, Gross CS, Schneider D, Jin F, Kretschmer PJ, Hermiston TW. Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV.. Cancer Gene Ther 2009 Feb;16(2):184-94.
    pubmed: 18758433doi: 10.1038/cgt.2008.68google scholar: lookup
  22. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007--an update.. J Gene Med 2007 Oct;9(10):833-42.
    pubmed: 17721874doi: 10.1002/jgm.1100google scholar: lookup
  23. Lenzi RN, Altevogt BM, Gostin LO. Oversight and Review of Clinical Gene Transfer Protocols: Assessing the Role of the Recombinant DNA Advisory Committee. Washington, DC: National Academies Press; 2014.
  24. Casadevall A, Pirofski LA. The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases.. PLoS Pathog 2015 Apr;11(4):e1004717.
    pmc: PMC4408073pubmed: 25905897doi: 10.1371/journal.ppat.1004717google scholar: lookup
  25. Wong G, Kobinger GP. Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.. Clin Microbiol Rev 2015 Jul;28(3):593-601.
    pmc: PMC4429225pubmed: 25972518doi: 10.1128/cmr.00014-15google scholar: lookup
  26. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors.. Stem Cells 2005 Feb;23(2):220-9.
    pubmed: 15671145doi: 10.1634/stemcells.2004-0166google scholar: lookup
  27. Ennis J, Götherström C, Le Blanc K, Davies JE. In vitro immunologic properties of human umbilical cord perivascular cells.. Cytotherapy 2008;10(2):174-81.
    pubmed: 18368596doi: 10.1080/14653240801891667google scholar: lookup
  28. Ennis J, Sarugaser R, Gomez A, Baksh D, Davies JE. Isolation, characterization, and differentiation of human umbilical cord perivascular cells (HUCPVCs).. Methods Cell Biol 2008;86:121-36.
    pubmed: 18442647doi: 10.1016/s0091-679x(08)00007-1google scholar: lookup
  29. Schugar RC, Chirieleison SM, Wescoe KE, Schmidt BT, Askew Y, Nance JJ, Evron JM, Peault B, Deasy BM. High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue.. J Biomed Biotechnol 2009;2009:789526.
    pmc: PMC2796378pubmed: 20037738doi: 10.1155/2009/789526google scholar: lookup
  30. Farias VA, Linares-Fernández JL, Peñalver JL, Payá Colmenero JA, Ferrón GO, Duran EL, Fernández RM, Olivares EG, O'Valle F, Puertas A, Oliver FJ, Ruiz de Almodóvar JM. Human umbilical cord stromal stem cell express CD10 and exert contractile properties.. Placenta 2011 Jan;32(1):86-95.
    pubmed: 21126763doi: 10.1016/j.placenta.2010.11.003google scholar: lookup
  31. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow.. Stem Cells 2007 Jun;25(6):1384-92.
    pubmed: 17332507doi: 10.1634/stemcells.2006-0709google scholar: lookup
  32. Vallejo CE. Characterization of Genetically Modified HUCPVCs as an Osteogeneic Cell Source. Toronto, ON, Canada: University of Toronto; 2013.
  33. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC. Venezuelan equine encephalitis.. Annu Rev Entomol 2004;49:141-74.
    pubmed: 14651460doi: 10.1146/annurev.ento.49.061802.123422google scholar: lookup
  34. Adams AP, Navarro-Lopez R, Ramirez-Aguilar FJ, Lopez-Gonzalez I, Leal G, Flores-Mayorga JM, Travassos da Rosa AP, Saxton-Shaw KD, Singh AJ, Borland EM, Powers AM, Tesh RB, Weaver SC, Estrada-Franco JG. Venezuelan equine encephalitis virus activity in the Gulf Coast region of Mexico, 2003-2010.. PLoS Negl Trop Dis 2012;6(11):e1875.
    pmc: PMC3486887pubmed: 23133685doi: 10.1371/journal.pntd.0001875google scholar: lookup
  35. Dal Canto MC, Rabinowitz SG. Central nervous system demyelination in Venezuelan equine encephalomyelitis infection.. J Neurol Sci 1981 Mar;49(3):397-418.
    pubmed: 7217991doi: 10.1016/0022-510x(81)90030-7google scholar: lookup
  36. Rivas F, Diaz LA, Cardenas VM, Daza E, Bruzon L, Alcala A, De la Hoz O, Caceres FM, Aristizabal G, Martinez JW, Revelo D, De la Hoz F, Boshell J, Camacho T, Calderon L, Olano VA, Villarreal LI, Roselli D, Alvarez G, Ludwig G, Tsai T. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995.. J Infect Dis 1997 Apr;175(4):828-32.
    pubmed: 9086137doi: 10.1086/513978google scholar: lookup
  37. Steele KE, Twenhafel NA. REVIEW PAPER: pathology of animal models of alphavirus encephalitis.. Vet Pathol 2010 Sep;47(5):790-805.
    pubmed: 20551475doi: 10.1177/0300985810372508google scholar: lookup
  38. Hawley RJ, Eitzen EM Jr. Biological weapons--a primer for microbiologists.. Annu Rev Microbiol 2001;55:235-53.
    pubmed: 11544355doi: 10.1146/annurev.micro.55.1.235google scholar: lookup
  39. Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine.. Vaccine 1996 Mar;14(4):337-43.
    pubmed: 8744562doi: 10.1016/0264-410x(95)00168-zgoogle scholar: lookup
  40. Gale S. Interscience Conference on Antimicrobial Agents and Chemotherapy--48th Annual Meeting and Infectious Diseases Society of America-- 46th Annual Meeting Updates on therapeutic research--Part 1.. IDrugs 2009 Jan;12(1):1-2.
    pubmed: 19127492
  41. Fine DL, Roberts BA, Terpening SJ, Mott J, Vasconcelos D, House RV. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates.. Vaccine 2008 Jun 25;26(27-28):3497-506.
    pubmed: 18508163doi: 10.1016/j.vaccine.2008.04.044google scholar: lookup
  42. Reed DS, Lind CM, Lackemeyer MG, Sullivan LJ, Pratt WD, Parker MD. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.. Vaccine 2005 May 2;23(24):3139-47.
    pubmed: 15837213doi: 10.1016/j.vaccine.2004.12.023google scholar: lookup
  43. Pratt WD, Davis NL, Johnston RE, Smith JF. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models.. Vaccine 2003 Sep 8;21(25-26):3854-62.
    pubmed: 12922119doi: 10.1016/s0264-410x(03)00328-1google scholar: lookup
  44. Hu WG, Chau D, Wu J, Jager S, Nagata LP. Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus.. Vaccine 2007 Apr 20;25(16):3210-4.
    pubmed: 17289226doi: 10.1016/j.vaccine.2007.01.034google scholar: lookup
  45. Hu WG, Phelps AL, Jager S, Chau D, Hu CC, O'Brien LM, Perkins SD, Gates AJ, Phillpotts RJ, Nagata LP. A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus.. Vaccine 2010 Aug 2;28(34):5558-64.
    pubmed: 20600509doi: 10.1016/j.vaccine.2010.06.038google scholar: lookup
  46. Treacy O, Ryan AE, Heinzl T, O'Flynn L, Cregg M, Wilk M, Odoardi F, Lohan P, O'Brien T, Nosov M, Ritter T. Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation.. PLoS One 2012;7(8):e42662.
    pmc: PMC3412834pubmed: 22880073doi: 10.1371/journal.pone.0042662google scholar: lookup
  47. Grinnemo KH, Månsson A, Dellgren G, Klingberg D, Wardell E, Drvota V, Tammik C, Holgersson J, Ringdén O, Sylvén C, Le Blanc K. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium.. J Thorac Cardiovasc Surg 2004 May;127(5):1293-300.
    pubmed: 15115985doi: 10.1016/j.jtcvs.2003.07.037google scholar: lookup
  48. Schmidt NJ, Dennis J, Lennette EH. Plaque reduction neutralization test for human cytomegalovirus based upon enhanced uptake of neutral red by virus-infected cells.. J Clin Microbiol 1976 Jul;4(1):61-6.
    pmc: PMC274391pubmed: 182716doi: 10.1128/jcm.4.1.61-66.1976google scholar: lookup
  49. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.. Nature 2014 Oct 2;514(7520):47-53.
    pmc: PMC4214273pubmed: 25171469doi: 10.1038/nature13777google scholar: lookup
  50. Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, Alimonti JB, Kobinger GP. mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms.. Sci Transl Med 2013 Oct 16;5(207):207ra143.
    pubmed: 24132638doi: 10.1126/scitranslmed.3006605google scholar: lookup
  51. Qiu X, Wong G, Fernando L, Ennis J, Turner JD, Alimonti JB, Yao X, Kobinger GP. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs.. J Virol 2013 Jul;87(13):7754-7.
    pmc: PMC3700280pubmed: 23616649doi: 10.1128/jvi.00173-13google scholar: lookup
  52. Stigbrand T, Ullén A, Sandström P, Rathsman S, Rossi Norrlund R, Arlestig L, Riklund Ahlström K, Hietala SO. Endogenous anti-tumor antibody responses in nude mice.. Cancer 1997 Dec 15;80(12 Suppl):2404-10.
    pubmed: 9406690doi: 10.1002/(sici)1097-0142(19971215)80:12+<2404::aid-cncr11>3.3.co;2-rgoogle scholar: lookup
  53. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies.. Nat Rev Immunol 2010 May;10(5):345-52.
    pubmed: 20414207doi: 10.1038/nri2747google scholar: lookup
  54. Bartholomew A, Patil S, Mackay A, Nelson M, Buyaner D, Hardy W, Mosca J, Sturgeon C, Siatskas M, Mahmud N, Ferrer K, Deans R, Moseley A, Hoffman R, Devine SM. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo.. Hum Gene Ther 2001 Aug 10;12(12):1527-41.
    pubmed: 11506695doi: 10.1089/10430340152480258google scholar: lookup
  55. . Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.. Pediatrics 1998 Sep;102(3 Pt 1):531-7.
    pubmed: 9738173
  56. Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells.. Exp Hematol 2000 Apr;28(4):382-90.
    pubmed: 10781896doi: 10.1016/s0301-472x(00)00134-xgoogle scholar: lookup
  57. Tsuda H, Wada T, Ito Y, Uchida H, Dehari H, Nakamura K, Sasaki K, Kobune M, Yamashita T, Hamada H. Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector.. Mol Ther 2003 Mar;7(3):354-65.
    pubmed: 12668131doi: 10.1016/s1525-0016(02)00062-xgoogle scholar: lookup
  58. Vilalta M, Dégano IR, Bagó J, Gould D, Santos M, García-Arranz M, Ayats R, Fuster C, Chernajovsky Y, García-Olmo D, Rubio N, Blanco J. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging.. Stem Cells Dev 2008 Oct;17(5):993-1003.
    pubmed: 18537463doi: 10.1089/scd.2007.0201google scholar: lookup
  59. Nakabayashi A, Kamei N, Sunagawa T, Suzuki O, Ohkawa S, Kodama A, Kamei G, Ochi M. In vivo bioluminescence imaging of magnetically targeted bone marrow-derived mesenchymal stem cells in skeletal muscle injury model.. J Orthop Res 2013 May;31(5):754-9.
    pubmed: 23192745doi: 10.1002/jor.22282google scholar: lookup

Citations

This article has been cited 8 times.
  1. Wang Y, Gao T, Li W, Tai C, Xie Y, Chen D, Liu S, Huang F, Wang W, Chen Y, Wang B. Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies. Cell Biosci 2023 Aug 31;13(1):160.
    doi: 10.1186/s13578-023-01099-zpubmed: 37653459google scholar: lookup
  2. Teryek M, Jadhav P, Bento R, Parekkadan B. 3D Microcapsules for Human Bone Marrow Derived Mesenchymal Stem Cell Biomanufacturing in a Vertical-Wheel Bioreactor. bioRxiv 2023 Feb 16;.
    doi: 10.1101/2023.02.16.528656pubmed: 36824906google scholar: lookup
  3. Chen G, Fan XY, Zheng XP, Jin YL, Liu Y, Liu SC. Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance via PTEN-mediated crosstalk between the PI3K/Akt and Erk/MAPKs signaling pathways in the skeletal muscles of db/db mice. Stem Cell Res Ther 2020 Sep 16;11(1):401.
    doi: 10.1186/s13287-020-01865-7pubmed: 32938466google scholar: lookup
  4. Lee TM, Harn HJ, Chiou TW, Chuang MH, Chen CH, Chuang CH, Lin PC, Lin SZ. Remote transplantation of human adipose-derived stem cells induces regression of cardiac hypertrophy by regulating the macrophage polarization in spontaneously hypertensive rats. Redox Biol 2019 Oct;27:101170.
    doi: 10.1016/j.redox.2019.101170pubmed: 31164286google scholar: lookup
  5. Wiese DM, Ruttan CC, Wood CA, Ford BN, Braid LR. Accumulating Transcriptome Drift Precedes Cell Aging in Human Umbilical Cord-Derived Mesenchymal Stromal Cells Serially Cultured to Replicative Senescence. Stem Cells Transl Med 2019 Sep;8(9):945-958.
    doi: 10.1002/sctm.18-0246pubmed: 30924318google scholar: lookup
  6. Sharma A, Knollmann-Ritschel B. Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development. Viruses 2019 Feb 18;11(2).
    doi: 10.3390/v11020164pubmed: 30781656google scholar: lookup
  7. Hamidian Jahromi S, Davies JE. Concise Review: Skeletal Muscle as a Delivery Route for Mesenchymal Stromal Cells. Stem Cells Transl Med 2019 May;8(5):456-465.
    doi: 10.1002/sctm.18-0208pubmed: 30720934google scholar: lookup
  8. Bian P, Ye C, Zheng X, Yang J, Ye W, Wang Y, Zhou Y, Ma H, Han P, Zhang H, Zhang Y, Zhang F, Lei Y, Jia Z. Mesenchymal stem cells alleviate Japanese encephalitis virus-induced neuroinflammation and mortality. Stem Cell Res Ther 2017 Feb 16;8(1):38.
    doi: 10.1186/s13287-017-0486-5pubmed: 28209182google scholar: lookup
Subscribe to our newsletter
Join 99,001 horse owners like you who receive our email updates on horse health and nutrition.